Login to Your Account



XenoPort Getting $75M Up Front

Late-Stage RLS Drug Lands XenoPort $640M GSK Deal

By Jennifer Boggs


Friday, February 9, 2007
XenoPort Inc. signed GlaxoSmithKline plc as a co-development and commercialization partner for XP13512, its lead product candidate in late-stage development for restless legs syndrome (RLS) and neuropathic pain. The deal could total up to $640 million in up-front and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription